Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 91

1.

Pubertal timing and breast density in young women: a prospective cohort study.

Houghton LC, Jung S, Troisi R, LeBlanc ES, Snetselaar LG, Hylton NM, Klifa C, Van Horn L, Paris K, Shepherd JA, Hoover RN, Dorgan JF.

Breast Cancer Res. 2019 Nov 14;21(1):122. doi: 10.1186/s13058-019-1209-x.

2.

Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.

Li W, Newitt DC, Wilmes LJ, Jones EF, Arasu V, Gibbs J, La Yun B, Li E, Partridge SC, Kornak J; I-SPY 2 Consortium, Esserman LJ, Hylton NM.

J Magn Reson Imaging. 2019 Dec;50(6):1742-1753. doi: 10.1002/jmri.26770. Epub 2019 Apr 26.

PMID:
31026118
3.

Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.

Jones EF, Ray KM, Li W, Chien AJ, Mukhtar RA, Esserman LJ, Franc BL, Seo Y, Pampaloni MH, Joe BN, Hylton NM.

NPJ Breast Cancer. 2019 Apr 16;5:12. doi: 10.1038/s41523-019-0107-9. eCollection 2019.

4.

Diffusion-weighted MRI in Multicenter Trials of Breast Cancer.

Partridge SC, Newitt DC, Chenevert TL, Rosen MA, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators.

Radiology. 2019 May;291(2):546. doi: 10.1148/radiol.2019190446. Epub 2019 Apr 2. No abstract available.

PMID:
30938630
5.

Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.

Newitt DC, Zhang Z, Gibbs JE, Partridge SC, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Aliu S, Li W, Cimino L, Joe BN, Umphrey H, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis J, Esserman LJ, Hylton NM; ACRIN Trial Team and I-SPY 2 TRIAL Investigators.

J Magn Reson Imaging. 2019 Jun;49(6):1617-1628. doi: 10.1002/jmri.26539. Epub 2018 Oct 22.

PMID:
30350329
6.

Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.

Partridge SC, Zhang Z, Newitt DC, Gibbs JE, Chenevert TL, Rosen MA, Bolan PJ, Marques HS, Romanoff J, Cimino L, Joe BN, Umphrey HR, Ojeda-Fournier H, Dogan B, Oh K, Abe H, Drukteinis JS, Esserman LJ, Hylton NM; ACRIN 6698 Trial Team and I-SPY 2 Trial Investigators.

Radiology. 2018 Dec;289(3):618-627. doi: 10.1148/radiol.2018180273. Epub 2018 Sep 4.

7.

Residual Disease after Neoadjuvant Therapy for Breast Cancer: Can MRI Help?

Hylton NM.

Radiology. 2018 Nov;289(2):335-336. doi: 10.1148/radiol.2018181846. Epub 2018 Aug 28. No abstract available.

8.

Exploration of PET and MRI radiomic features for decoding breast cancer phenotypes and prognosis.

Huang SY, Franc BL, Harnish RJ, Liu G, Mitra D, Copeland TP, Arasu VA, Kornak J, Jones EF, Behr SC, Hylton NM, Price ER, Esserman L, Seo Y.

NPJ Breast Cancer. 2018 Aug 16;4:24. doi: 10.1038/s41523-018-0078-2. eCollection 2018.

9.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1219-1235. doi: 10.1016/j.ijrobp.2018.06.023. Epub 2018 Jun 30. Review.

10.

MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.

Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, Pisano ED, Marques HS, Morris EA, Weatherall PT, Polin SM, Newstead GM, Esserman LJ, Schnall MD, Hylton NM; ACRIN 6657 Trial Team and I-SPY Investigators Network.

AJR Am J Roentgenol. 2018 Jun;210(6):1376-1385. doi: 10.2214/AJR.17.18323. Epub 2018 Apr 30.

11.

Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices.

Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN.

Radiology. 2018 Mar;286(3):822-829. doi: 10.1148/radiol.2017170811. Epub 2017 Oct 25.

12.

Accuracy, repeatability, and interplatform reproducibility of T1 quantification methods used for DCE-MRI: Results from a multicenter phantom study.

Bane O, Hectors SJ, Wagner M, Arlinghaus LL, Aryal MP, Cao Y, Chenevert TL, Fennessy F, Huang W, Hylton NM, Kalpathy-Cramer J, Keenan KE, Malyarenko DI, Mulkern RV, Newitt DC, Russek SE, Stupic KF, Tudorica A, Wilmes LJ, Yankeelov TE, Yen YF, Boss MA, Taouli B.

Magn Reson Med. 2018 May;79(5):2564-2575. doi: 10.1002/mrm.26903. Epub 2017 Sep 14.

13.

Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer.

Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM.

Clin Breast Cancer. 2017 Jun;17(3):e155-e159. doi: 10.1016/j.clbc.2016.12.008. Epub 2016 Dec 29. No abstract available.

PMID:
28110902
14.

Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL.

Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM; ACRIN 6657 Trial Team and I-SPY Investigators Network.

Tomography. 2016 Dec;2(4):378-387. doi: 10.18383/j.tom.2016.00247.

15.

MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial.

Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM; ACRIN Trial team ISPY-1 Investigators.

J Magn Reson Imaging. 2017 Jul;46(1):290-302. doi: 10.1002/jmri.25560. Epub 2016 Dec 16.

16.

Diffusion Tensor Imaging for Assessment of Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer.

Wilmes LJ, Li W, Shin HJ, Newitt DC, Proctor E, Harnish R, Hylton NM.

Tomography. 2016 Dec;2(4):438-447. doi: 10.18383/j.tom.2016.00271.

17.

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.

Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):23-34. doi: 10.1056/NEJMoa1513749.

18.

Adaptive Randomization of Neratinib in Early Breast Cancer.

Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators.

N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750.

19.

Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women.

Bertrand KA, Baer HJ, Orav EJ, Klifa C, Kumar A, Hylton NM, LeBlanc ES, Snetselaar LG, Van Horn L, Dorgan JF.

Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1151-7. doi: 10.1158/1055-9965.EPI-16-0185. Epub 2016 May 9.

20.

Variability and bias assessment in breast ADC measurement across multiple systems.

Keenan KE, Peskin AP, Wilmes LJ, Aliu SO, Jones EF, Li W, Kornak J, Newitt DC, Hylton NM.

J Magn Reson Imaging. 2016 Oct;44(4):846-55. doi: 10.1002/jmri.25237. Epub 2016 Mar 23.

21.

Design of a breast phantom for quantitative MRI.

Keenan KE, Wilmes LJ, Aliu SO, Newitt DC, Jones EF, Boss MA, Stupic KF, Russek SE, Hylton NM.

J Magn Reson Imaging. 2016 Sep;44(3):610-9. doi: 10.1002/jmri.25214. Epub 2016 Mar 7.

22.

Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes.

Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM.

PLoS One. 2016 Feb 17;11(2):e0142047. doi: 10.1371/journal.pone.0142047. eCollection 2016.

23.

Quantitative Imaging in Cancer Clinical Trials.

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.

Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. Review.

24.

Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL.

Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators.

Radiology. 2016 Apr;279(1):44-55. doi: 10.1148/radiol.2015150013. Epub 2015 Dec 1.

25.

Body fatness during childhood and adolescence and breast density in young women: a prospective analysis.

Bertrand KA, Baer HJ, Orav EJ, Klifa C, Shepherd JA, Van Horn L, Snetselaar L, Stevens VJ, Hylton NM, Dorgan JF.

Breast Cancer Res. 2015 Jul 16;17:95. doi: 10.1186/s13058-015-0601-4.

26.

Adolescent endogenous sex hormones and breast density in early adulthood.

Jung S, Egleston BL, Chandler DW, Van Horn L, Hylton NM, Klifa CC, Lasser NL, LeBlanc ES, Paris K, Shepherd JA, Snetselaar LG, Stanczyk FZ, Stevens VJ, Dorgan JF.

Breast Cancer Res. 2015 Jun 4;17:77. doi: 10.1186/s13058-015-0581-4.

27.

Multi-site clinical evaluation of DW-MRI as a treatment response metric for breast cancer patients undergoing neoadjuvant chemotherapy.

Galbán CJ, Ma B, Malyarenko D, Pickles MD, Heist K, Henry NL, Schott AF, Neal CH, Hylton NM, Rehemtulla A, Johnson TD, Meyer CR, Chenevert TL, Turnbull LW, Ross BD.

PLoS One. 2015 Mar 27;10(3):e0122151. doi: 10.1371/journal.pone.0122151. eCollection 2015.

28.

Extra-mammary findings on breast MRI: a pictorial review.

Karp NL, Price ER, Wisner DJ, Chang CB, Hylton NM, Joe BN.

Clin Imaging. 2015 Jul-Aug;39(4):547-52. doi: 10.1016/j.clinimag.2015.01.019. Epub 2015 Feb 24. Review.

PMID:
25772531
29.

The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer.

DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ.

Clin Cancer Res. 2015 Jul 1;21(13):2911-5. doi: 10.1158/1078-0432.CCR-14-1760. Epub 2015 Feb 24.

30.

Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis.

Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1464-83. doi: 10.1158/1055-9965.EPI-13-1170. Epub 2014 May 7. Review.

31.

Repeatability of quantitative MRI measurements in normal breast tissue.

Aliu SO, Jones EF, Azziz A, Kornak J, Wilmes LJ, Newitt DC, Suzuki SA, Klifa C, Gibbs J, Proctor EC, Joe BN, Hylton NM.

Transl Oncol. 2014 Feb 1;7(1):130-7. eCollection 2014 Feb.

32.

Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform.

Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM.

Transl Oncol. 2014 Feb 1;7(1):94-100. eCollection 2014 Feb.

33.

High resolution in vivo characterization of apparent diffusion coefficient at the tumor-stromal boundary of breast carcinomas: a pilot study to assess treatment response using proximity-dependent diffusion-weighted imaging.

McLaughlin RL, Newitt DC, Wilmes LJ, Jones EF, Wisner DJ, Kornak J, Proctor E, Joe BN, Hylton NM.

J Magn Reson Imaging. 2014 May;39(5):1308-13. doi: 10.1002/jmri.24283. Epub 2013 Oct 8.

34.

Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy.

Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM.

J Magn Reson Imaging. 2014 Aug;40(2):476-82. doi: 10.1002/jmri.24351. Epub 2013 Dec 18.

35.

High-resolution diffusion-weighted imaging for the separation of benign from malignant BI-RADS 4/5 lesions found on breast MRI at 3T.

Wisner DJ, Rogers N, Deshpande VS, Newitt DN, Laub GA, Porter DA, Kornak J, Joe BN, Hylton NM.

J Magn Reson Imaging. 2014 Sep;40(3):674-81. doi: 10.1002/jmri.24416. Epub 2013 Nov 8.

36.

Features of occult invasion in biopsy-proven DCIS at breast MRI.

Wisner DJ, Hwang ES, Chang CB, Tso HH, Joe BN, Lessing JN, Lu Y, Hylton NM.

Breast J. 2013 Nov-Dec;19(6):650-8. doi: 10.1111/tbj.12201.

37.

Menstrual and reproductive characteristics and breast density in young women.

Dorgan JF, Klifa C, Deshmukh S, Egleston BL, Shepherd JA, Kwiterovich PO Jr, Van Horn L, Snetselaar LG, Stevens VJ, Robson AM, Lasser NL, Hylton NM.

Cancer Causes Control. 2013 Nov;24(11):1973-83. doi: 10.1007/s10552-013-0273-2. Epub 2013 Aug 10.

38.

Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.

Bolouri MS, Elias SG, Wisner DJ, Behr SC, Hawkins RA, Suzuki SA, Banfield KS, Joe BN, Hylton NM.

Radiology. 2013 Nov;269(2):354-61. doi: 10.1148/radiol.13130058. Epub 2013 Jul 22.

39.

Accuracy and interpretation time of computer-aided detection among novice and experienced breast MRI readers.

Lehman CD, Blume JD, DeMartini WB, Hylton NM, Herman B, Schnall MD.

AJR Am J Roentgenol. 2013 Jun;200(6):W683-9. doi: 10.2214/AJR.11.8394.

40.

Recognizing artifacts and optimizing breast MRI at 1.5 and 3 T.

Yitta S, Joe BN, Wisner DJ, Price ER, Hylton NM.

AJR Am J Roentgenol. 2013 Jun;200(6):W673-82. doi: 10.2214/AJR.12.10013. Review.

PMID:
23701101
41.

MRI enhancement in stromal tissue surrounding breast tumors: association with recurrence free survival following neoadjuvant chemotherapy.

Jones EF, Sinha SP, Newitt DC, Klifa C, Kornak J, Park CC, Hylton NM.

PLoS One. 2013 May 7;8(5):e61969. doi: 10.1371/journal.pone.0061969. Print 2013.

42.

High-resolution diffusion-weighted imaging for monitoring breast cancer treatment response.

Wilmes LJ, McLaughlin RL, Newitt DC, Singer L, Sinha SP, Proctor E, Wisner DJ, Saritas EU, Kornak J, Shankaranarayanan A, Banerjee S, Jones EF, Joe BN, Hylton NM.

Acad Radiol. 2013 May;20(5):581-9. doi: 10.1016/j.acra.2013.01.009.

43.

Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.

De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Meric-Bernstam F, Meszoely IM, Nanda R, Hwang ES.

Cancer. 2013 May 15;119(10):1776-83. doi: 10.1002/cncr.27995. Epub 2013 Feb 21.

44.

Height, adiposity and body fat distribution and breast density in young women.

Dorgan JF, Klifa C, Shepherd JA, Egleston BL, Kwiterovich PO, Himes JH, Gabriel K, Horn L, Snetselaar LG, Stevens VJ, Barton BA, Robson AM, Lasser NL, Deshmukh S, Hylton NM.

Breast Cancer Res. 2012 Jul 13;14(4):R107. doi: 10.1186/bcr3228.

45.

Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.

Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD; ACRIN 6657 Trial Team and I-SPY 1 TRIAL Investigators.

Radiology. 2012 Jun;263(3):663-72. doi: 10.1148/radiol.12110748.

46.

High-resolution diffusion-weighted magnetic resonance imaging in patients with locally advanced breast cancer.

Singer L, Wilmes LJ, Saritas EU, Shankaranarayanan A, Proctor E, Wisner DJ, Chang B, Joe BN, Nishimura DG, Hylton NM.

Acad Radiol. 2012 May;19(5):526-34. doi: 10.1016/j.acra.2011.11.003. Epub 2011 Dec 22.

47.

Diffusion-weighted MRI: influence of intravoxel fat signal and breast density on breast tumor conspicuity and apparent diffusion coefficient measurements.

Partridge SC, Singer L, Sun R, Wilmes LJ, Klifa CS, Lehman CD, Hylton NM.

Magn Reson Imaging. 2011 Nov;29(9):1215-21. doi: 10.1016/j.mri.2011.07.024. Epub 2011 Sep 14.

48.

Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ.

Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES.

Breast. 2011 Dec;20(6):529-33. doi: 10.1016/j.breast.2011.06.001. Epub 2011 Aug 16.

49.

MRI appearance of tumor recurrence in myocutaneous flap reconstruction after mastectomy.

Peng C, Chang CB, Tso HH, Flowers CI, Hylton NM, Joe BN.

AJR Am J Roentgenol. 2011 Apr;196(4):W471-5. doi: 10.2214/AJR.10.5279.

PMID:
21427313
50.

Can signal enhancement ratio (SER) reduce the number of recommended biopsies without affecting cancer yield in occult MRI-detected lesions?

Arasu VA, Chen RC, Newitt DN, Chang CB, Tso H, Hylton NM, Joe BN.

Acad Radiol. 2011 Jun;18(6):716-21. doi: 10.1016/j.acra.2011.02.008. Epub 2011 Mar 21.

Supplemental Content

Loading ...
Support Center